Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

Abstract: The present disclosure advantageously refers to systems and methods for predicting an oil mixture's blend compatibility without mixing the components and/or without performing direct blend testing. The techniques described use a correlation between near infrared spectroscopic information, asphaltene solubility parameter Ra, and maltene solubility parameter Po to accurately predict blend compatibility using the equation P=Po(blend)/Ra(blend). A P?1 indicates the blend is compatible. These techniques are useful in, for example, refineries to predict and therefore reduce or eliminate fouling due to asphaltene deposits.

Abstract: The present disclosure advantageously refers to systems and methods for predicting an oil mixture's blend compatibility without mixing the components and/or without performing direct blend testing. The techniques described use a correlation between near infrared spectroscopic information, asphaltene solubility parameter Ra, and maltene solubility parameter Po to accurately predict blend compatibility using the equation P=Po(blend)/Ra(blend). A P?1 indicates the blend is compatible. These techniques are useful in, for example, refineries to predict and therefore reduce or eliminate fouling due to asphaltene deposits.

Abstract: The invention concerns methods of using a ketamine dosage form in treating depression and, in particular, major depressive disorder and treatment-resistant depression, comprising administering to a patient in need thereof, a fast dissolving freeze-dried wafer solid dosage form with a matrix for rapid release and absorption of ketamine in the oral cavity of the said patient.

Abstract: A method is provided for predicting conjunct polymer concentration in spent ionic liquid during a continuous hydrocarbon conversion process.

Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: A method is provided for predicting conjunct polymer concentration in spent ionic liquid during a continuous hydrocarbon conversion process.

Abstract: Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Abstract: Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Abstract: Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Abstract: Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Abstract: A method of estimating the relative concentration of at least two components contained in a mixture of the components is disclosed. At least two mixtures are produced by combining the at least two components, each of the at least two mixtures having different concentrations of the at least two components. NIR mixture spectra are acquired from each of the at least two mixtures. The NIR component spectra and the NIR mixture spectra are input into a computer utilizing chemometrics software and the spectra are analyzed to produce a calibration model for each component and each of the mixture NIR spectra. NIR monitored spectra for a monitored mixture of the components having an unknown concentration of the components is acquired. The calibration models are applied to the NIR monitored spectra to thereby estimate the concentration of at least one of the components in the monitored mixture.

Abstract: A method of estimating the relative concentration of at least two components contained in a mixture of the components is disclosed. At least two mixtures are produced by combining the at least two components, each of the at least two mixtures having different concentrations of the at least two components. NIR mixture spectra are acquired from each of the at least two mixtures. The NIR component spectra and the NIR mixture spectra are input into a computer utilizing chemometrics software and the spectra are analyzed to produce a calibration model for each component and each of the mixture NIR spectra. NIR monitored spectra for a monitored mixture of the components having an unknown concentration of the components is acquired. The calibration models are applied to the NIR monitored spectra to thereby estimate the concentration of at least one of the components in the monitored mixture.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.